Lexicon Pharmaceuticals vs NewAmsterdam Pharma
LXRX and NAMS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LXRX and NAMS compare
Lexicon Pharmaceuticals grew revenue faster over the last twelve months (−29.0% versus −88.9% for NewAmsterdam Pharma).
Lexicon Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −147% compared with −3644% at NewAmsterdam Pharma.
NewAmsterdam Pharma scores higher on the StockData Score (6 against 5 for Lexicon Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LXRX | NAMS |
|---|---|---|
| Size and price | ||
| Market cap | $792M | – |
| Share price | $1.78 | $19.39 |
| Change, 1 year | 19.5% | −49.4% |
| Change, 5 years | −62.4% | 98.1% |
| Beta (5Y) | 0.01 | 1.57 |
| Employees | 81 | 100 |
| StockData Score | ||
| Total score | 5 | 6 (better) |
| Valuation score | 0 | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 2 (better) | 1 |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 19.1× | – |
| P/B | 4.5× | – |
| Fair value | $0.950 | – |
| Margin of safety | −87.4% | – |
| Growth | ||
| Revenue growth (TTM) | −29.0% (better) | −88.9% |
| Revenue growth, 5Y average | 15.7% | – |
| Profitability | ||
| Gross margin | 99.1% | – |
| Operating margin | −131% (better) | −3432% |
| Net margin | −147% (better) | −3644% |
| FCF margin | – | −2018% |
| Return on equity | −40.2% | −36.8% (better) |
| Return on invested capital | −163% (better) | −1046% |
| Financial health | ||
| Debt / equity | 0.29 (better) | 0.00 |
| Current ratio | 13.37 (better) | 9.03 |
| Altman Z-score | −4.87 | – |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 81.9% | – |
| Held by insiders | – | 22.0% |
| Insider net buying, 12 months | $2.8M (better) | −$63.0M |
Go deeper
- LXRX stock overview
- LXRX income statement
- LXRX valuation and score
- NAMS stock overview
- NAMS income statement
- NAMS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.